Hematology
High bleeding rates are not associated with short-term triple therapy among patients undergoing PCI
Published in Hematology Week, September 4th, 2006
Investigators working in Israel aimed to "assess bleeding complications among patients undergoing percutaneous coronary intervention (PCI) and receiving triple therapy of warfarin, aspirin, and a thienopyridine."
A. Porter and colleagues at Rabin Medical Center in Petah-Tikva wrote, "Triple therapy of warfarin, aspirin, and a thienopyridine is strongly discouraged, given the potential risk of bleeding complications. Post-PCI patients receiving triple therapy thereafter underwent assessment for bleeding...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hematology Week
Source: Hematology Week (2006-09-04)
More Articles from Hematology Week
- Erythropoiesis
Vascular endothelial growth factor modulates erythropoiesis - Hematology
Alternatively spliced tissue factor is a previously unknown piece in the puzzle of hemostasis - Leukemia
Leukemia favorable outcome predicted by simplified flow cytometric assay - Acute Myeloid Leukemia
Dacogen (decitabine) for Injection receives U.S. orphan drug designation for patients with AML - Acute Myeloid Leukemia
Positive phase II study of Bcl-2 antisense plus gemtuzumab ozogamicin reported - Adipose Tissue
Adipose tissue could be a good source of cells for short-term hematopoiesis reconstitution - More from this issue of Hematology Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
